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Hereditary surfactant protein-B (SP-B) deficiency is a rare autosomal recessive 
disease of newborn infants causing severe respiratory failure and death within 
the first year of life. The most common cause of SP-B deficiency is a frameshift 
mutation in exon 4 (121ins2) in the gene encoding SP-B. We report a term 
infant with unremitting respiratory distress who was unresponsive to all 
treatment modalities. The parents were consanguineous and a term sibling 
of the infant had died due to respiratory failure without a certain diagnosis. 
In the first step of the diagnostic work-up, common genetic mutations for 
SP-B, surfactant protein C and ATP-binding cassette s3 were absent, however 
sequencing of SP-B gene revealed a large homozygous genomic deletion 
covering exon 8 and 9. 
In this case report, we aimed to emphasize further genetic evaluation in all 
cases suggestive of surfactant dysfunction, even if common mutations are 
absent.
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Respiratory problems are common in the early 
neonatal period and take an extensive place 
in the neonatal practice. A majority of cases 
are premature infants with respiratory distress 
syndrome or chronic lung disease. However, 
there are a significant number of full-term 
infants admitted to the neonatal intensive 
care units for respiratory distress. Beside well 
known diseases, such as transient tachypnea of 
the newborn, meconium aspiration syndrome, 
pulmonary hypertension and pneumonia, 
some diseases are very rare and constitute 
a diagnostic challenge in full-term infants. 
These mainly include miscellaneous infections, 
structural abnormalities of the lung and genetic 
disorders of surfactant dysfunction.1,2 
Here, we report the case of a full-term infant 
with severe respiratory distress with a very 
rare type of surfactant protein-B (SP-B) gene 
mutation. 
Case Report
A 38-week-gestation male infant with a birth 
weight of 3,130 g was delivered by cesarean 
section to a 24 year old gravida 2, para 2 
mother after an uneventful pregnancy. His 
parents were first cousins. The mother had 
no known prenatal disease history such as 
infection or diabetes. The sibling of the infant, 
who was born at full-term had died at 15 
days of age with pulmonary hypertension and 
a suspicion of congenital pneumonia. The 
Apgar scores were 8 and 8 at 1 and 5 min, 
respectively. The infant developed respiratory 
distress 1 hour after birth. The physical 
examination revealed grunting, cyanosis and 
tachypnea with subcostal and intercostal 
retractions. Initially, he was transferred to 
the neonatal intensive care unit and received 
continuous positive airway pressure (CPAP) 
support with a 50% supplemental oxygen. A 
treatment regimen of intravenous ampicillin and 
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gentamicin therapy, was also started. Despite 
respiratory support and antibiotic therapy, the 
infant’s clinical condition deteriorated over a 
few hours. He was intubated and ventilated 
with conventional mechanical ventilation. 
Chest radiography showed a diffuse granular 
pattern compatible with surfactant deficiency 
(Fig. 1). Echocardiography was normal. A 
200 mg/kg dose of exogenous surfactant 
treatment was given on the first day of life. 
The infant was extubated and treated with 
CPAP soon after surfactant administration. 
On the third day of life, the infant’s health 
degraded and the baby was put on conventional 
mechanical ventilation again. Dopamine and 
dobutamine were administered to maintain 
normal blood pressure. Second and third 
doses of exogenous surfactant were given 
on the third and sixth days of life, which 
resulted in a mild and transient improvement 
on oxygenation. Repeated evaluations for 
infections were negative, with normal white 
blood count, immature/total neutrophil ratio, 
C-reactive protein and negative blood cultures. 
During the following days, respiratory failure 
progressed. FiO2 was increased to 1.0 and the 
ventilation treatment was changed to high 
frequency oscillatory ventilation. Low dose of 
intravenous dexamethasone therapy was added 
to the treatment on day 30. However, all these 
approaches failed to improve severe hypoxemia 
and respiratory acidosis. The infant died of 
respiratory failure at 43 days of life. Informed 
Fig. 2. Histopathologic examination of the lung tissue. 
Intraalveolar accumulation of eosinophilic hyaline 
membranes are shown (haematoxylin-eosin stain, original 
magnification x 20)
Fig. 1. Chest radiography showed a diffuse granular 
pattern compatible with severe RDS
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consent for genetic testing for hereditary 
surfactant deficiencies and post-mortem open 
lung biopsy were obtained from the parents. 
Histopathologic examination of the lung tissue 
showed diffuse collapse of the airspaces and 
eosinophilic hyaline membranes lining the 
remaining alveolar spaces (Fig. 2).
The initial genetic evaluation revealed the 
absence of common mutations of SFTPB 
(121ins2), surfactant protein C [SFTPC (173T)] 
and ATP-binding cassette protein subfamily A 
[(ABCA3) (E292V)]. Also no mutation has 
been identified in the entire coding sequence 
and exon-intron junctions of SFTPC and ABCA3 
genes. subsequent DNA sequencing of SFTPB 
identified a very rare large homozygous 
genomic deletion c.708+194_1039-28del or 
chr2. hg38: g.85665095_85662137del spanning 
2959 base pairs and covering exon 8 and 9 of 
the SFTPB gene (NM-000542.3) Both parents 
were heterozygous for that gene mutation, 
confirming an autosomal recessive pattern 
of inheritance. A schematic representation 
of a breakpoint spanning PCR validating the 
deletion in the index patient and his parents 
is shown in Figure 3.
Informed consent was obtained from the 
parents of the infant for presenting this case.
Discussion
The pulmonary surfactant is a complex mixture 
of phospholipids and proteins needed to 
reduce alveolar surface tension and to prevent 
end-expiratory collapse. The phospholipid 
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component represents approximately 90% of the 
surfactant that performs the surface-tension-
lowering function. The protein component 
forms the remaining 10% by weight of the 
surfactant. Surfactant proteins are necessary 
for surfactant biosynthesis and metabolism and 
to provide immune functions. There are four 
surfactant proteins named SP-A, SP-B, SP-C and 
SP-D. SP-A and SP-D participate in host defense 
in the lung, whereas SP-B and SP-C play an 
important role in the metabolism and dynamics 
of the lipids of pulmonary surfactant3. As the 
structure and function of the surfactant proteins 
are different, the clinical outcome of the 
surfactant protein deficiency could be variable. 
Particularly SP-B is the only surfactant protein 
strictly required for breathing, as indicated by 
previous experimental studies and case reports 
Fig. 3. (a) SFTPB genomic sequence of the newborn patient around the breakpoint and schematic representation of part 
of the SFTPB gene (RefSeq: NM_000542.3) exons are indicated as blocks, introns as lines and PCR primers as arrows. 
(b) PCR amplification of genomic DNA from the newborn patient (lane 3), parents (lanes 1 and 2) and an unaffected 
control (lane 4). 100-bp molecular weight marker (lane M), only buffer without DNA (lane bl). In the newborn patient 
exons 8 and 9 of SFTPB were not amplified in the corresponding PCR  reaction, while a PCR product was obtained 
by using PCR primers 7 forward (7F) and  10 reverse (10R). The same amplicon (PCR 7F/10R)  was amplified in the 
parents and not in the unaffected control suggesting  the presence of a homozygous large rearrangement in the patient.
showing that the inability to produce SP-B 
results in lethal respiratory failure.4,5
Hereditary SP-B deficiency is a rare autosomal 
recessive disease, first recognized in full-term 
infants in 1993.6 Affected infants develop 
severe progressive respiratory failure in spite 
of all aggressive treatment modalities. Clinical 
estimates suggest that SP-B deficiency has an 
incidence of 1 per million live births, whereas 
the frequency of the 121ins2 mutation is 
approximately 1 per 1000 individuals3. SP-B is 
encoded by SFTPB gene located on the short 
arm of chromosome 2 and consists of 12 exons 
(exon 1 and 12 non-coding) (NM_000542.3, 
variant 1). More than 40 distinct mutations 
have been identified in the SFTPB gene to date. 
The most common mutation, which amounts 
to two thirds of the mutant alleles, is a net 
2-bp insertion at codon 121 in exon 4 of the 
SFTPB (121ins2). 
Although the incidence is very rare, SP-B 
deficiency is suggested to be underdiagnosed. 
These infants commonly present with 
unremitting hypoxemic respiratory failure 
after an uncomplicated pregnancy and delivery. 
Regarding the autosomal recessive inherited 
pattern, a family history of affected siblings 
may present in some cases.7 In the present 
case, the full-term infant was born after an 
uneventful pregnancy and his respiration 
deteriorated within hours after delivery. The 
parents were consanguineous and had already 
lost a child due to respiratory failure. Based on 
the clinical manifestations, we suspected the 
possibility of a surfactant mutation that could 
affect the SFTPB and ABCA3 genes. The most 
frequent gene mutations in these two genes, 
121ins2 for SFTPB and E292V for ABCA3, were 
not found during the first step of our genetic 
testing. Additional sequencing analysis showed 
a large homozygous genomic deletion of the 
SFTPB gene, described as c.708+194_1039-
28del (NM_000542.3). This deletion produces 
the loss of in-frame exons 8-9, generating a 
protein lacking amino acids 225-334 (p.Gly225_
Lys334del) (NP_000533.3). To date, a variety 
of SFTPB mutations were described including 
nonsense, missense, frameshift, and splice-site 
mutations, as well as minor insertions and 
deletions through the gene. Large deletions 
spanning exons 7 and 8, corresponding to 
exons 8 and 9 (NM_000542.3) have also been 
reported previously in two separate cases.5,8 To 
the best of our knowledge, our case is the third 
case encompassing multiple exons of the SFTPB 
gene. The descent of our patient is Turkish and 
the previous infants are Azerbaijani and Kurdish 
suggesting that this type of SFTPB mutation 
may have an importance in these regions.
The differential diagnoses include hereditary 
ABCA3 deficiency and congenital alveolar 
capillary dysplasia with misalignment of 
pulmonary veins (ACDMPV).9 Analysis of post 
mortem lung tissue ruled out ACDMPV, since 
none of the prominent pathologic features, such 
as decrease number of pulmonary capillaries 
located away from the alveolar epithelium and 
hypertrophy of pulmonary arteries, could be 
observed. 
As a limitation of the case, an immunochemical 
analysis demonstrating the absence of SP-B 
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could not be performed due to technical 
restrictions.
No specific treatment for SP-B deficiency 
is available to date. Exogenous surfactant 
is ineffective and provides only transient 
improvement in gas exchange. Currently, 
the only described successful treatment of 
SP-B deficiency is lung transplantation. After 
transplantation, the 5-year survival rate is 
approximately 50%.3 Identifying the disease-
causing mutation in the index case however, 
allows to provide genetic counseling to the 
affected families. Parents described in this case 
received preimplantation genetic diagnosis and 
had a healthy baby. 
In conclusion, full-term infants with profound 
respiratory failure and who appear refractory to 
all treatment modalities are strong candidates 
for the evaluation of hereditary SP-B deficiency. 
We emphasize further genetic evaluation in all 
cases suggestive of surfactant dysfunction, even 
if common mutations are absent. 
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